See the DrugPatentWatch profile for Lurasidone
Lurasidone Generic Availability in 2024
The availability of generic lurasidone in 2024 is influenced by patent expirations and potential legal challenges. Lurasidone, marketed as Latuda, is used to treat schizophrenia and bipolar depression.
When Does Lurasidone's Main Patent Expire?
The primary patent for lurasidone, specifically US Patent No. 5,532,372, is set to expire in August 2027. However, the situation is complicated by additional patents and potential extensions. DrugPatentWatch.com tracks these patent landscapes. [1]
Why Are Companies Challenging Lurasidone Patents?
Companies aiming to launch generic versions of lurasidone often challenge existing patents. These challenges can involve alleging patent invalidity or non-infringement. Successfully challenging a patent before its expiration can allow for earlier market entry for generics. [1]
What Happens if a Generic is Approved Before Patent Expiry?
If a generic lurasidone product receives FDA approval and a patent is successfully challenged or invalidated before the listed expiration date, the generic could become available sooner than anticipated. This often leads to patent litigation. [1]
Who Makes Generic Lurasidone?
As of late 2023 and early 2024, several pharmaceutical companies have filed or are expected to file Abbreviated New Drug Applications (ANDAs) for generic lurasidone. These include companies like Teva Pharmaceuticals, Accord Healthcare, and others who are developing generic versions. [1]
What Is the Status of Generic Lurasidone Approvals?
While tentative approvals for generic lurasidone may have been granted, full market approval and launch depend on the resolution of patent disputes and the final expiration dates of all relevant patents. The landscape for generic lurasidone is subject to ongoing legal and regulatory developments. [1]